• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

COVID-19 Home-Testing Kit Could Soon be Available for Purchase in UK

Share:

March 31, 2020

Public Health England (PHE) informed the UK government that (25 March) home-testing kits that identify whether a person has ever been infected with COVID-19 could soon be available to order online and from chemists,.

The simple finger-prick test should take no more than 15 minutes and will see members of the public extract blood from home and send their sample off for evaluation.

It will not test whether someone has the virus currently but if they have already recovered from it, potentially allowing them to return to a more normal daily routine. It will also provide information on how widespread the virus is.

WHY IT MATTERS

Professor Sharon Peacock, director of the National Infection Service for PHE, told the government’s Health and Science select committee that the tests were going through the customary evaluation but that it was “a small matter” that would be “done by the end of the week”.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Professor Chris Whitty, the UK government’s CMO, however, was less optimistic about the timeline. Shortly after Professor Peacock’s address, he stated: “I do not think – and I want to be clear – that this is something we’ll suddenly be ordering on the internet next week”.

The UK government has already purchased 3.5 million tests, which they say will be rolled out once their efficacy has been assured.

Priority testing will be given to key workers, particularly in the NHS as increasing numbers of healthcare workers self-isolate, concerned that they have contracted the virus. The at-home test will be able to ascertain whether it is safe for workers to return to work after the virus has passed.

The test is reliant on the widely-held belief that reinfection with the virus is either not possible or rare.

THE LARGER PICTURE

Within the last week, the UK has fallen behind on the number of tests it is carrying out. Although aiming to test 25,000 cases a day in the next few weeks, it is suffering from a lack of resources and availability of staff to carry these out.

On 24th March, 6,491 tests were carried out, a slight increase in line with WHO’s recommendation that countries “test, test, test” to help tackle the pandemic.

Due to the testing deficit, private companies have offered unverified tests that PHE have condemned, including one (no longer available) which cost users £375.

ON THE RECORD

Professor Peacock said: “Several million [pin-prick] tests have been purchased for use. These are brand new products. We have to be clear they work as they are claimed to do. Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community”.

Professor Whitty responded: “The key thing for us to do is evaluate, are these tests accurate enough to be used by the general public? If they are incredibly accurate, we will work out the quickest way to release them. If they are not accurate, we will not release any of them”.

He continued: “We need to help make sure we can get NHS workers tested to make sure we can work out who is immune or almost certainly immune to this infection and who isn’t. We need to go through the evaluation, then the first critical uses, and then spread it out from that point of view […] in a systematic way”.

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • 24 Lessons From Warren Buffett’s Annual Letters To Shareholders24 Lessons From Warren Buffett’s Annual Letters To Shareholders
  • Amp Recover CEO Talks Digital Health Adoption in Orthopedics, PT, Sports MedAmp Recover CEO Talks Digital Health Adoption in Orthopedics, PT, Sports Med
  • Quinolone Antibiotic Market 2020: COVID Impact, Industrial Growth, Regional Analysis, Trends and Forecasts 2024Quinolone Antibiotic Market 2020: COVID Impact, Industrial Growth, Regional Analysis, Trends and Forecasts 2024
  • Cybersecurity: The Hidden Health Tech Crisis No One’s Talking AboutCybersecurity: The Hidden Health Tech Crisis No One’s Talking About
  • Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver DiseasesAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
  • AHIMA to Provide MEDITECH Expanse EHR Training to 16k StudentsAHIMA to Provide MEDITECH Expanse EHR Training to 16k Students
  • CRH Medical acquires 1st Washington GI anesthesia practice — 4 insightsCRH Medical acquires 1st Washington GI anesthesia practice — 4 insights
  • Helping VA to Combat Infectious Disease Across the Full Continuum of CareHelping VA to Combat Infectious Disease Across the Full Continuum of Care

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications